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Objectives.We determined metabolic syndrome (MetS) prevalence and assessed the agreement between different diagnostic criteria
in HIV-infected South Africans.Method. A random sample included 748 HIV-infected adult patients (79% women) across 17 HIV
healthcare facilities in the Western Cape Province. MetS was defined using the Joint Interim Statement (JIS 2009), International
Diabetes Federation (IDF 2005), and Adult Treatment Panel III (ATPIII 2005) criteria. Results. Median values were 38 years
(age), 5 years (diagnosed HIV duration), and 392 cells/mm3 (CD4 count), and 93% of the participants were on antiretroviral
therapy (ART). MetS prevalence was 28.2% (95%CI: 25–31.4), 26.5% (23.3–29.6), and 24.1% (21–27.1) by the JIS, IDF, and
ATPIII 2005 criteria, respectively. Prevalence was always higher in women than in men (all p < 0 001), in participants with
longer duration of diagnosed HIV (all p ≤ 0 003), and in ART users not receiving 1st-line regimens (all p ≤ 0 039). The
agreement among the three criteria was very good overall and in most subgroups (all kappa ≥ 0 81). Conclusions. The three most
popular diagnostic criteria yielded similarly high MetS prevalence in this relatively young population receiving care for HIV
infection. Very good levels of agreement between criteria are unaffected by some HIV-specific features highlighting the likely
comparable diagnostic utility of those criteria in routine HIV care settings.
1. Introduction
The introduction of multiple components antiretroviral
therapy (ART) has led to a global decline in AIDS-related
mortality among HIV-infected people, with the disease
now regarded as a chronic condition. It remains, however,
a major contributor to the global burden of disease, with
HIV-infected individuals now succumbing to non-AIDS-
related comorbidities. These are commonly associated with
unhealthy lifestyle behaviours and ageing, similar to the gen-
eral population, and are a testimony to the success of ART in
extending lifespans. Cardiovascular diseases (CVDs) and
their cardiometabolic risk factors of hypertension, type 2
diabetes mellitus (hereafter referred to as diabetes), dyslipi-
daemia, and obesity are rising health priorities in the HIV-
infected population [1, 2]. Notably, these cardiometabolic
conditions appear to be more prevalent and to occur at
younger ages in the HIV-infected compared to noninfected
populations [3].
Cardiometabolic diseases are known to frequently cluster
with this constellation referred to as the metabolic syndrome
(MetS). A diagnosis of MetS is important because it identifies
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individuals at increased risk for CVDs, diabetes, and all-
cause mortality [4]. The pathophysiology of MetS in HIV-
infected individuals is thought to be complex with HIV
infection per se, prolonged use of ART drugs, and traditional
CVD risk factors contributing to the process [5]. Moreover,
weight gain may occur following the uptake of ART, with
the use of protease inhibitors (PIs) or nucleoside reverse
transcriptase inhibitors (NRTIs), in particular, leading to
body fat depositions in the abdominal and dorsal regions;
this may further contribute to the development of MS
among HIV-infected individuals [6].
Considering the possible additional pathways, and thus
the subsequent greater risk for the development of MetS in
HIV-infected individuals, it is essential to determine the
MetS prevalence in this population. According to a recent
meta-analysis, the prevalence of MetS in the HIV-infected
was 17–31% worldwide, depending on the diagnostic criteria
used [7]. Although South Africa has the greatest number of
HIV-infected individuals, who account for 17% of the global
HIV/AIDS population [8], there is a dearth of literature on
the MetS in the local HIV-infected population. Such data is
required to guide the appropriate allocation of resources
and the development of cost-effective therapeutic strategies
and programmes for MetS care in the HIV-infected individ-
uals. Furthermore, it underscores the importance of a holistic
approach in the management of HIV-infected individuals.
Thus, this study aimed to determine the MetS prevalence in
HIV-infected patients receiving care at public healthcare
facilities in the Western Cape Province of South Africa using
various diagnostic criteria and to assess the agreement
between these criteria.
2. Research Design and Methods
2.1. Study Population and Sampling. A cross-sectional study
was conducted between March 2014 and February 2015
among HIV-infected men and women aged 18 years and
older, who received care at primary healthcare facilities in
the Western Cape. Details of the study method have been
described previously [9]. In brief, the participants were sam-
pled from 17 healthcare facilities including 10 facilities in
Cape Town and seven in the surrounding rural municipali-
ties using random sampling procedures. Patients who were
pregnant or breastfeeding, bedridden, undergoing treatment
for cancer, on corticosteroid treatment, unwilling, or unable
to give consent were excluded from the study.
The study was approved by the South African Medical
Research Council Ethics Committee and conducted in accor-
dance with the principles of the Declaration of Helsinki. Per-
mission to conduct the survey was obtained from the Health
Research Office of the Western Cape Department of Health
and the selected healthcare facilities.
2.2. Data Collection. A team of trained clinicians, nurses, and
fieldworkers collected the data using questionnaires, clinical
measurements, and biochemical analyses. The data were cap-
tured on personal digital assistants (PDAs), using the elec-
tronic case report forms with built-in checks for quality
control. These were then encrypted at the point of collection
and sent via mobile connections to a dedicated server where
it was further checked, downloaded, and stored for future
use. While the interviews and physical examinations were
done on the day of recruitment, blood samples were taken
the following day after the participant had fasted overnight.
Sociodemographicdata andmedical historywereobtained
using a structured interviewer-administered questionnaire
adapted from the World Health Organization’s (WHO)
STEPwise approach to Surveillance (STEPS) tool. Duration
of diagnosed HIV infection, CD4 count, and ART regimens
were obtained from participants’ records. The 1st-line regi-
men was a combination of 2 nucleoside reverse transcriptase
inhibitors (2NRTIs) andanonnucleoside reverse transcriptase
inhibitor (NNRTI),while the 2nd regimens combined 2nucle-
oside reverse transcriptase inhibitors (2NRTIs) and a boosted
protease inhibitor (2PIs) [10].
Anthropometric measurements used standardised tech-
niques. Heights and weights were taken with the participants
in light clothing and barefooted. Waist circumference (WC)
to the nearest centimetre was measured at the level of umbi-
licus. Blood pressure (BP) was measured on the right arm,
using a digital automatic BP monitor (Omron M6 Comfort,
Netherlands) after the participant was seated in a resting
position for at least five minutes; three measurements were
taken three minutes apart whereas the average value of the
2nd and 3rd measurements was used as BP level in the
analysis.
Biochemical parameters were analyzed at an ISO 15189
accreditedpathology laboratory (PathCare,ReferenceLabora-
tory,CapeTown, SouthAfrica). Serumcholesterol and triglyc-
erides were analyzed by enzymatic colorimetric methods;
plasma glucose was measured by the hexokinase method; all
are implemented using a Beckman Coulter AU 500 spectro-
photometer. Insulin concentrations were measured by the
chemiluminescence immunoassay method. The homeostatic
model assessment of insulin resistance (HOMA-IR) was cal-
culated as the product of insulin (mIU/L) and glucose
(mmol/L) by 22.5 [11].
2.3. Definitions of MetS. Several international organisations
have proposed various definitions for MetS [12]. Those con-
sidered in the current study were the European Group for the
Study of Insulin Resistance criteria (EGIR 1999) [13], ATPIII
2005 [14], IDF 2005 [15], and JIS 2009 [12], described in
Table 1. Both WHO and EGIR definitions have proposed
insulin resistance as a prerequisite for diagnosing the MetS.
EGIR defines insulin resistance as plasma insulin levels above
75th percentile from nondiabetes populations [13] while
WHO recommends the use of hyperinsulinaemic euglycae-
mic clamp—glucose uptake values below 25th percentile
[16]. Because the hyperinsulinaemic euglycaemic clamp and
urinary albumin excretion assessments were not undertaken
in our study, the WHO criteria were excluded from our
analysis [16].
2.4. Statistical Analysis. The R statistical software version
3.0.3 (March 6, 2014) was used for statistical analysis. The
numerical variables are expressed as means (±SD) or
medians (25th–75th percentiles) and categorical variables as
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counts and percentages. Groups’ comparison used the
Mann–Whitney U test and chi-square test as appropriate.
The agreement between the diagnostic criteria for the MetS
was assessed with the use of the kappa statistics. Kappa
statistics values are interpreted as poor (kappa ≤ 0 2), fair
(0.2 < kappa ≤ 0 4), moderate (0.4 < kappa ≤ 0 6), substantial
(0.6 < kappa ≤ 0 8), and very good (kappa > 0 8) [17]. In the
main analysis, we determined the prevalence of the MetS by
the ATPIII 2005, the IDF, and the JIS criteria and assessed
the agreement between these three criteria. The criteria were
then expanded to include the EGIR criteria in secondary
analyses of a subsample of participants with data available
on insulin resistance. A p value of 0.05 is considered statisti-
cally significant.
3. Results
3.1. Characteristics of the Participants.Of the 831 participants
recruited, 748 had complete data on all components of the
MetS and are included in the present analyses. As presented
in Table 2, 79% (591 participants) of the sample consisted of
women. The median age of the participants was 38 years
(25th–75th percentiles: 32–44), with men significantly older
thanwomen (41 years versus 37 years, p < 0 001). Themedian
duration of diagnosed HIV infection was 5 years (25th–75th
percentiles: 2–9) with women diagnosed longer than men (5
years versus 4 years, p < 0 001). The median CD4 count was
392 cells/mm3 (25th–75th percentiles: 240–604) with counts
higher in women (410 cells/mm3, 253–627) compared to
men (272 cells/mm3, 193–448), p = 0 001. Most participants
(93%) were on ART, with the majority being 1st-line ART
users (61%) and the distribution of ART regimens differing
in men and women (p = 0 005). Compared with men, women
were more likely to have greater BMI, waist circumference,
total cholesterol, low-density lipoprotein cholesterol (LDL-
C), high-density lipoprotein cholesterol (HDL-C), and
HOMA index (all p ≤ 0 012) but had a lower waist-to-hip
ratio (WHR), systolic BP, triglycerides (TGs), and fasting
plasma glucose (FPG) levels (all p ≤ 0 023).
3.2. Prevalence of the Metabolic Syndrome by the JIS, IDF,
and ATPIII 2005 Criteria. The prevalence of MetS (95%CI)
by the JIS, IDF, and ATPIII 2005 criteria was 28.2% (25–
31.4), 26.5% (23.3–29.6), and 24.1% (21–27.1), respectively
(Table 3). The MetS prevalence was significantly higher in
women compared to men across the three criteria (all
p < 0 001): JIS (31.3% versus 16.6%), IDF (30.5% versus
11.5%), and ATPIII 2005 (26.9% versus 13.4%).
The prevalence of MetS by the HIV-related characteris-
tics is also presented in Table 3. MetS prevalence was higher
in participants with ≥5 years’ compared with <5 years’ dura-
tion of diagnosed HIV infection (all p ≤ 0 003): JIS (32.6%
versus 22.5%), IDF (30.5% versus 21%), and ATPIII 2005
(28.8% versus 17.9%). With regard to ART use, the preva-
lence of MetS in the 46 participants who were not on ART
was 34.8% (21–48.6) by the JIS and 32.6% (19.1–46.2) by
the IDF and ATPIII 2005 criteria. This was not significantly
different compared to those on ART (all p ≥ 0 175). Across
the three criteria by ART regimens, participants on 1st-line
ART regimens had lowerMetS prevalence comparedwith 2nd
lineorotherregimens,(allp ≤ 0 039).Therewasatrendtowards
higherMetSprevalencewithCD4count ≥ 392cells/mm3com-
pared with <392 cells/mm3. However, these were not signifi-
cantly different by any of the three criteria (all p ≥ 0 06): JIS
(32.6% versus 25.3%), IDF (32.1% versus 24.7%), and ATPIII
2005 (29.4%versus 21.0%).
Table 1: Criteria used for the diagnosis of the metabolic syndrome.
Criteria EGIR (1999) [13] ATPIII (2005) [14] IDF (2005) [15] JIS (2009) [12]
Compulsory
IR, fasting insulin > 75th
percentile
None
WC ≥ 94 cm (men)
WC ≥ 80 cm (women)
None
Additional Any 2 other criteria Any 3 criteria Any 2 other criteria Any 3 criteria
Obesity
Men WC ≥ 94 cm WC ≥ 102 cm — WC ≥ 94 cm
Women WC ≥ 80 cm WC ≥ 88 cm WC ≥ 80 cm
Triglycerides >2.0mmol/L ≥1.7mmol/L ≥1.7mmol/L ≥1.7mmol/L
HDL-C
Men <1.0mmol/L <1.03mmol/L <1.03mmol/L <1.03mmol/L














Glucose ≥6.1mmol/L ≥5.6mmol/L or on diabetes
treatment
≥5.6mmol/L or on diabetes
treatment
≥5.6mmol/L or on diabetes
treatment
ATPIII: Adult Treatment Panel III; EGIR: European Group for the Study of Insulin Resistance; IDF: International Diabetes Federation; JIS: Joint Interim
Statement; HDL-C: high-density lipoprotein cholesterol; IR: insulin resistance; WC: waist circumference.
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3.3. Concordance between Different MetS Criteria. The con-
cordance between the JIS, IDF, and ATPIII 2005 MetS cri-
teria overall and by subgroups is shown in Table 4. The
overall agreement was very good with a kappa of 0.96
(95%CI: 0.93–0.98) between the JIS and IDF criteria, 0.89
(95%CI: 0.86–0.93) between the JIS and ATPIII 2005 cri-
teria, and 0.84 (95%CI: 0.80–0.89) between the IDF and
ATPIII 2005 criteria. Similarly, high levels of agreement
were found in women, by subgroups of diagnosed HIV
infection duration, CD4 count, and ART regimens. The level
of concordance in men was very good between the JIS and
ATPIII 2005 criteria [kappa 0.88 (0.77–0.98)] but lower
between the JIS and IDF criteria [kappa=0.79 (0.65–0.93)]
and the IDF and ATPIII 2005 criteria [0.62 (0.43–0.81)].
3.4. SecondaryAnalyses in Participants with Insulin Resistance
Data. In the subgroup of participants with data available on
insulin resistance (N = 711), the prevalence of MetS and the
agreement between the JIS, IDF, and ATPIII 2005 criteria,
overall and within subgroups, were mostly similar to those
observed in the main analysis (see Table S1 and Table S2 in
Supplementary Material available online at https://doi.org/
10.1155/2017/1613657). In this subsample, the prevalence of
MetS according to the EGIR criteria was as follows: overall:
12.4%; men versus women: 6.7% versus 13.9%, p = 0 018;
shorter versus longer duration of diagnosed HIV infection:
9.5% versus 15.2%, p = 0 022; CD4 count < 392 cells/mm3
versus ≥392 cells/mm3: 7.9% versus 17.2, p = 0 007; and
ART regimens: 10.1% (1st line), 19.4% (2nd line), and
14.4% (other regimens) (p = 0 051) (Table S1). The agree-
ment between EGIR and the other criteria was at most
fair: EGIR versus JIS 0.33 (0.25–0.40); EGIR versus IDF
0.32 (0.24–0.40); and EGIR versus ATPIII 2005 0.38
(0.30–0.46) (Table S2).
4. Discussion
In the present study among HIV-infected participants who
were mostly on ART, we found that (1) the prevalence of
MetS was high based on the JIS, IDF, and ATPIII 2005 cri-
teria but much lower by the EGIR criteria; (2) across the
MetS definitions, the prevalence appeared to be higher
among women, participants with longer duration of diag-
nosed HIV infection, and ART users not receiving 1st-line
regimens but was mostly unaffected by CD4 count levels;
and (3) the agreement between the JIS, IDF, and ATPIII
Table 2: Characteristics of the HIV-infected participants.
Characteristics Total Men Women
p valueMedian (25th–75th percentiles) N = 748 N = 157 N = 591
Age (years) 38 (32–44) 41 (35–47) 37 (31–43) <0.001
Anthropometry
Body mass index (kg/m2) 26.3 (22.1–32) 21.4 (19.8–22.4) 28.3 (23.8–28.9) <0.001
Waist circumference (cm) 88 (78–98) 79 (74–88) 90 (80–101) <0.001
Waist-to-hip ratio 0.86 (0.8–0.91) 0.87 (0.84–0.93) 0.85 (0.8–0.9) <0.001
Blood pressure (mmHg)
Systolic 117 (107–130) 123.5 (114.5–140) 115 (105.8–127) <0.001
Diastolic 82 (75–91) 83 (76–94) 81.5 (74.8–89.8) 0.129
Lipid variables (mmol/L)
Total cholesterol 4.3 (3.7–5.1) 4.2 (3.5–3.8) 4.4 (3.8–5.1) 0.009
LDL-C 2.5 (2.0–3.1) 2.3 (1.7–3.0) 2.5 (2.0–3.1) 0.012
HDL-C 1.3 (1–1.5) 1.2 (1.0–1.5) 1.29 (1.08–1.52) 0.010
Triglycerides 1 (0.7–1.3) 1.12 (0.75–1.27) 0.97 (0.74–1.28) 0.023
Fasting glucose (mmol/L) 5 (4.6–5.4) 5.1 (4.8–5.5) 4.9 (4.6–5.4) 0.010
HOMA-IR 1.36 (0.84–2.24) 0.94 (0.53–1.64) 1.49 (0.93–2.37) <0.001
HIV-related factors
HIV duration (years) 5 (2–9) 4 (2–7) 5 (2.5–9) <0.001
CD4 count (cells/mm3) 392 (240–604) 272 (193–448) 410 (253–627) 0.001
Number (%) N = 699 N = 149 N = 550
Antiretroviral treatment 0.005
None 46 (6.6) 7 (4.7) 39 (7.1)
1st line 426 (60.9) 78 (52.3) 348 (63.3)
2nd line 79 (11.3) 17 (11.4) 62 (11.3)
Others 148 (21.2) 47 (31.5) 101 (18.3)
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HIV: human immunodeficiency virus; HOMA index: homeostatic
model assessment of insulin resistance.
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2005 was very good overall and in most subgroups, while the
agreement of the three criteria with EGIR was generally fair.
4.1. MetS Prevalence by Different Criteria in the HIV-Infected
Population. The prevalence of the MetS in this study by the
different criteria was in line with the findings of a recent
meta-analysis which revealed that nearly one-third of global
HIV-infected populations have the MetS [7]. Compared with
other criteria, the JIS identified the most participants with
MetS, which was not surprising. The higher thresholds for
WC in the ATPIII 2005 and the mandatory use of WC in
the IDF criteria likely ruled out the participants diagnosed
with MetS by the JIS criteria but who did not qualify for cen-
tral obesity based on the IDF or ATPIII criteria. Similarly, the
presence of insulin resistance and the higher thresholds for
TG and FPG, as well as lower thresholds for HDL-C in
women in the EGIR criteria, would explain the differences
in the magnitude of MetS prevalence between EGIR and
the three other set of criteria.
4.2. Comparison of MetS Prevalence in the HIV-Infected and
General Populations. The MetS prevalence in this study was
within the range of 17–46% published in the general popula-
tion internationally [18–20] and locally [21, 22]. Studies on
the epidemiology of MetS in South Africa have provided
the prevalent rates of 30.7% in urban black residents of Cape
Town [22] and 26.5% in black adults in rural KwaZulu-
Natal with the JIS criteria [21]. Using the JIS, IDF, and
ATPIII 2001 criteria, and in a much older (mean age of 51
years) and highly obese urban colored population in Cape
Town, Erasmus and coworkers found MetS prevalence of
62%, 60.6%, and 55.4%, respectively [23].
The higher prevalence of MetS among women compared
to men in this study is consistent with the recent meta-
analysis of MetS in people with HIV infection [7], and in line
with the prevalence reports of MetS in the general popula-
tion [21–23]. Notably, the similarities in prevalent MetS
between young HIV-infected people and a much older gen-
eral population suggest the likely comparable risk of devel-
oping MetS-related conditions such as CVDs and diabetes
in people with HIV infection, but at a much younger age.
4.3. MetS Prevalence and HIV-Related Characteristics.Higher
prevalence of MetS was found among participants with lon-
ger duration of diagnosed HIV infection and ART users
who were not on 1st-line regimens. These associations may
in part be explained by older age and drug-related toxicity
secondary to prolonged use of ART [24] or the 2nd-line reg-
imens that contain protease inhibitors (PIs). Results of clini-
cal trials suggest that PI-based regimens accelerate the
Table 3: Prevalence (95% confidence interval) of the metabolic syndrome by the JIS, IDF, and ATPIII 2005 criteria presented by gender and
HIV-related subgroups.
Subgroups JIS p value IDF p value ATPIII 2005 p value
Gender (n = 748)
Overall 28.2 (25.0–31.4) <0.001 26.5 (23.3–29.6) <0.001 24.1 (21.0–27.1) <0.001
Men 16.6 (10.8–22.4) 11.5 (6.5–16.5) 13.4 (8.1–18.7)
Women 31.3 (27.6–35.0) 30.5 (26.8–34.2) 26.9 (23.3–30.5)
HIV duration (n = 740)
Overall 27.8 (24.6–31.1) 0.002 26.1 (22.9–29.2) 0.003 23.7 (20.6–26.7) 0.001
HIV duration < 5 yrs 22.5 (18.1–26.9) 21.0 (16.8–25.3) 17.9 (13.8–21.9)
HIV duration ≥ 5 yrs 32.6 (27.9–37.2) 30.5 (26.0–35.1) 28.8 (24.3–33.2)
CD4 count (n = 373)
Overall 29 (24.4–33.6) 0.118 28.4 (23.8–33) 0.115 25.2 (20.8–29.6) 0.060
CD4 count < 392 25.3 (19.0–31.5) 24.7 (18.5–30.9) 21.0 (15.1–26.8)
CD4 count ≥ 392 32.6 (25.9–39.3) 32.1 (25.4–38.8) 29.4 (22.9–35.9)
ART use (n = 699)
Overall 28.0 (24.7–31.4) 0.292 26.2 (22.9–29.4) 0.305 24.3 (21.1–27.5) 0.175
No ART 34.8 (21.0–48.6) 32.6 (19.1–46.2) 32.6 (19.1–46.2)
On ART 27.6 (24.1–31.0) 25.7 (22.4–29.1) 23.7 (20.5–27.0)
ART regimens 0.017 0.031 0.039
1st line 23.9 (19.9–28.0) 22.5 (18.6–26.5) 20.7 (16.8–24.5)
2nd line 32.9 (22.5–43.3) 29.1 (19.1–39.1) 30.4 (20.2–40.5)
Others 35.1 (27.4–42.8) 33.1 (25.5–40.7) 29.1 (21.7–36.4)
Data are percentage and 95% confidence intervals; ATPIII: Adult Treatment Panel III; EGIR: European Group for the Study of Insulin Resistance; IDF:
International Diabetes Federation; JIS: Joint Interim Statement; HIV: human immunodeficiency virus; ART: antiretroviral therapy. Data were missing for
some characteristics. For each grouping variable for which data were missing for some participants, the number of participants with valid data is provided
(attached to the name of the variable), as well as the overall prevalence of metabolic syndrome in that subsample.
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progression of MetS, likely via chronic inflammation and
incomplete restoration of the immune system after com-
mencing ART [25, 26]. The lack of effect of CD4 count or
ART use, mainly with 1st-line regimens, on the presence of
MetS reported in this study, mirrors the results of a recent
meta-analysis [7]. It is of note however that the effect of
CD4 count was explored in a relatively small sample, with a
possibility of low statistical power.
4.4. Agreement between Sets of Criteria. In the present study,
the agreement between JIS, IDF, and ATPIII 2005 criteria
was generally good, implying that with the exception of some
subgroups, these sets of criteria generally classify the same
individuals as having MetS, or ruled out the diagnosis in
the same people. This is not surprising since all three criteria
are based on the same components although not always with
the same threshold for waist circumference. Generally, the
agreement between EGIR and other three criteria was at most
fair. The key feature explaining the low agreement was the
use of insulin resistance as a criterion in the EGIR definition.
Only two studies have previously assessed the agreement
between MetS criteria in HIV-infected people, and these
have provided findings mostly in line with ours. Ayodele
and colleagues reported a very good agreement between JIS
and IDF criteria (kappa= 0.88) [27], whereas the agreement
between IDF and EGIR was fair (kappa=0.30) in the report
by Cubero and coworkers [28].
The degree of agreement between the JIS, IDF, and
ATPIII 2005 criteria in this study is consistent with data from
studies conducted in general populations in Africa [21, 23,
29, 30] and other parts of the world [31–33] with the agree-
ment being better in women than in men [29, 30, 33]. Fur-
thermore, the agreement in our sample was unaffected by
HIV-specific characteristics, supporting the comparable
Table 4: Kappa statistics and 95% confidence interval for the concordance between the JIS, IDF, and ATPIII 2005 metabolic syndrome
criteria presented by gender and HIV-related subgroups (N = 748).
Group and subgroup Criteria IDF JIS
Overall (n = 748) IDF — 0.96 (0.93–0.98)
ATPIII 2005 0.84 (0.80–0.89) 0.89 (0.86–0.93)
Men
IDF — 0.79 (0.65–0.93)
ATPIII 2005 0.62 (0.43–0.81) 0.88 (0.77–0.98)
Women
IDF — 0.98 (0.96–1.00)
ATPIII 2005 0.87 (0.83–0.92) 0.89 (0.85–0.93)
HIV duration—overall (n = 740) IDF — 0.96 (0.93–0.98)
ATPIII 2005 0.84 (0.80–0.89) 0.89 (0.85–0.93)
HIV duration < 5 yrs
IDF — 0.96 (0.92–0.99)
ATPIII 2005 0.81 (0.73–0.89) 0.86 (0.79–0.92)
HIV duration ≥ 5 yrs
IDF — 0.95 (0.92–0.99)
ATPIII 2005 0.86 (0.80–0.92) 0.91 (0.87–0.95)
CD4 count—overall (n = 373) IDF — 0.99 (0.97–1.00)
ATPIII 2005 0.89 (0.84–0.94) 0.91 (0.86–0.95)
CD4 count < 392 cells/mm3 IDF — 0.99 (0.96–1.00)
ATPIII 2005 0.86 (0.78–0.95) 0.88 (0.80–0.96)
CD4 count ≥ 392 cells/mm3 IDF — 0.99 (0.96–1.00)
ATPIII 2005 0.91 (0.85–0.98) 0.93 (0.87–0.98)
Antiretroviral therapy use—overall (n = 699) IDF — 0.95 (0.93–0.98)
ATPIII 2005 0.85 (0.81–0.90) 0.90 (0.87–0.94)
No antiretroviral treatment
IDF — 0.95 (0.86–1.00)
ATPIII 2005 0.9 (0.77–1.00) 0.95 (0.86–1.00)
On antiretroviral treatment
IDF — 0.95 (0.93–0.98)
ATPIII 2005 0.85 (0.80–0.90) 0.90 (0.86–0.94)
1st-line antiretroviral therapy regimen
IDF — 0.96 (0.93–0.99)
ATPIII 2005 0.86 (0.80–0.92) 0.91 (0.86–0.95)
2nd-line antiretroviral therapy regimen
IDF — 0.91 (0.81–1.00)
ATPIII 2005 0.85 (0.72–0.98) 0.94 (0.86–1.00)
Other antiretroviral therapy regimens
IDF — 0.95 (0.90–1.00)
ATPIII 2005 0.81 (0.71–0.91) 0.86 (0.77–0.95)
ATPIII: Adult Treatment Panel III; IDF: International Diabetes Federation; JIS: Joint Interim Statement; HIV: human immunodeficiency virus. Data were
missing for some characteristics. For each grouping variable for which data were missing for some participants, the overall agreement between criteria in
that subsample is provided.
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diagnostic performance of the commonest sets of diagnostic
criteria for MetS in a broader population of people with
HIV infection and across the continuum of HIV care.
4.5. Strengths and Limitations. The present study has some
limitations. The relatively fewer men and ART-naïve partic-
ipants may lead to unstable estimates of MetS prevalence in
these subgroups. The absence of an HIV-negative subgroup
limits the direct comparison of our findings with those in
the general population. In addition, missing data on HIV-
related variables did not allow us to perform a regression
analysis, which limited the identification of HIV-specific
associations with MetS in our study.
Considering that most HIV-related studies in Africa are
single-clinic-based, a major strength of this study is the
inclusion of multiple healthcare facilities. Moreover, the
included healthcare facilities, selected using random sam-
pling methods, were based in both urban and rural areas
known to influence MetS prevalence. This allows for the
generalizability of the results to other South African HIV-
infected population. Furthermore, this study has provided
the most comprehensive analysis of the agreement between
MetS diagnostic criteria in people with HIV infection.
5. Conclusions
This study has reported a high prevalence of MetS according
to the three recent criteria in young adult South Africans with
HIV infection, and the likely influence of some, but not all,
HIV-related characteristics on the estimates. The very good
agreement between these sets of criteria suggests that their
sequential application is unlikely to explain differences in
MetS prevalence in HIV-infected people across settings and
time periods, nor would result in substantial mismatch of
individuals’ MetS status if these criteria were applied inter-
changeably in routine settings for the purpose of risk screen-
ing and reduction. However, previous studies have advised
against uncritical application to the general population in
Africa, of internationally advocated diagnostic thresholds
for some common parameters to these criteria such as WC,
as this could lead to unacceptable MetS risk stratification.
Extending these investigations to people with HIV infection
should be part of future efforts to promote MetS screening
in HIV-infected population in Africa using any of the set of
criteria applied in the current study.
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